Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of MLN0128 (TAK-228) in Patients With Advanced Non-Small Cell Lung Cancers Harboring NFE2L2 and KEAP1 Mutations

NCT02417701 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02417701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02417701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of MLN0128 (TAK-228) in Patients With Advanced Non-Small Cell Lung Cancers Harboring NFE2L2 and KEAP1 Mutations
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
October 6, 2016
Completion date
December 28, 2020
Enrollment
34 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent lung squamous cell carcinoma, stage iv lung squamous cell carcinoma ajcc v7